MRTX - BeiGene's tislelizumab combo study shows antitumor activity in solid tumors

BeiGene (BGNE) presents clinical data on tislelizumab, in combination with sitravatinib being jointly developed with Mirati Therapeutics (MRTX) at the American Association for Cancer Research ((AACR)) Annual Meeting 2021.Data presented were from two cohorts of Phase 1b trial in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patients with advanced platinum-resistant ovarian cancer ((PROC)). Results in Patients with Unresectable or Metastatic Melanoma Refractory or Resistant to PD-1/L1 Inhibitors: All 25 patients were evaluable for efficacy and the confirmed ORR was 24% (95% CI: 9.4, 45.1), including six partial responses (PRs), and the disease control rate ((DCR)) was 88% (95% CI: 68.8, 97.5).The media duration of response (DoR) was not reached, and the median PFS was 6.7 months (95% CI: 4.07, not evaluable).All 25 patients experienced at least one treatment-emergent adverse event ((TEAE)) of any grade Treatment; two patients (8%) discontinued the treatment due to

For further details see:

BeiGene's tislelizumab combo study shows antitumor activity in solid tumors